K. Bertelsen

3.8k total citations
70 papers, 2.3k citations indexed

About

K. Bertelsen is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, K. Bertelsen has authored 70 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Reproductive Medicine, 25 papers in Oncology and 24 papers in Surgery. Recurrent topics in K. Bertelsen's work include Ovarian cancer diagnosis and treatment (43 papers), Endometrial and Cervical Cancer Treatments (15 papers) and Intraperitoneal and Appendiceal Malignancies (12 papers). K. Bertelsen is often cited by papers focused on Ovarian cancer diagnosis and treatment (43 papers), Endometrial and Cervical Cancer Treatments (15 papers) and Intraperitoneal and Appendiceal Malignancies (12 papers). K. Bertelsen collaborates with scholars based in Denmark, Belgium and United Kingdom. K. Bertelsen's co-authors include Anders Jakobsen, Berit Hølund, A Sell, Jørn Andersen, Ignace Vergote, Søren M. Bentzen, J. Kærn, P. Sevelda, Nina Einhorn and Joos Vandewalle and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

K. Bertelsen

68 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Bertelsen Denmark 25 1.4k 1.1k 849 769 296 70 2.3k
Harrison Ball United States 22 1.6k 1.1× 1.1k 1.0× 534 0.6× 994 1.3× 315 1.1× 47 2.4k
Giovanna Scarfone Italy 28 1.6k 1.1× 771 0.7× 844 1.0× 987 1.3× 287 1.0× 83 2.6k
M. Lahousen Austria 22 1.2k 0.8× 665 0.6× 348 0.4× 1.0k 1.3× 298 1.0× 82 1.9k
Bonnie Reichman United States 29 1.7k 1.2× 1.7k 1.6× 1.7k 1.9× 468 0.6× 429 1.4× 69 3.4k
George J. Olt United States 16 902 0.6× 680 0.6× 767 0.9× 941 1.2× 297 1.0× 38 2.3k
H Lambert United Kingdom 19 930 0.7× 575 0.5× 473 0.6× 359 0.5× 232 0.8× 50 1.7k
Pamela J. Paley United States 26 1.3k 0.9× 542 0.5× 392 0.5× 903 1.2× 196 0.7× 41 2.2k
C. Lhommé France 30 1.4k 1.0× 940 0.9× 677 0.8× 1.2k 1.6× 447 1.5× 147 2.8k
J.G. Aalders Netherlands 22 1.2k 0.9× 713 0.7× 453 0.5× 1.4k 1.9× 276 0.9× 64 2.5k
Michael Teneriello United States 17 1.6k 1.1× 535 0.5× 1.1k 1.2× 512 0.7× 308 1.0× 33 2.3k

Countries citing papers authored by K. Bertelsen

Since Specialization
Citations

This map shows the geographic impact of K. Bertelsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Bertelsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Bertelsen more than expected).

Fields of papers citing papers by K. Bertelsen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Bertelsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Bertelsen. The network helps show where K. Bertelsen may publish in the future.

Co-authorship network of co-authors of K. Bertelsen

This figure shows the co-authorship network connecting the top 25 collaborators of K. Bertelsen. A scholar is included among the top collaborators of K. Bertelsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Bertelsen. K. Bertelsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mirza, Mansoor Raza, Bente Lund, Jacob Christian Lindegaard, et al.. (2010). A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin. Gynecologic Oncology. 119(1). 26–31. 8 indexed citations
2.
Nielsen, Jens Steen, Erik Jakobsen, Berit Hølund, K. Bertelsen, & Anders Jakobsen. (2004). Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. International Journal of Gynecological Cancer. 14(6). 1086–1096. 115 indexed citations
3.
Piccart, Martine, K. Bertelsen, Gavin Stuart, et al.. (2002). Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer. Annals of Oncology. 5 indexed citations
4.
Bertelsen, K., Seija Grénman, & G.J.S. Rustin. (1999). How long should first-line chemotherapy continue?. Annals of Oncology. 10. S17–S20. 5 indexed citations
5.
Rustin, Gordon, Ann E. Nelstrop, Søren M. Bentzen, Martine Piccart, & K. Bertelsen. (1999). Use of tumour markers in monitoring the course of ovarian cancer. Annals of Oncology. 10. S21–S27. 15 indexed citations
6.
Rustin, Gordon, Ann E. Nelstrop, Søren M. Bentzen, Martine Piccart, & K. Bertelsen. (1999). Use of tumour markers in monitoring the course of ovarian cancer.. Annals of Oncology. 10(1). 21–27. 53 indexed citations
7.
Jakobsen, Anders, K. Bertelsen, Jørn Andersen, et al.. (1997). Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.. Journal of Clinical Oncology. 15(1). 193–198. 114 indexed citations
8.
Bertelsen, K., et al.. (1995). What have we achieved in ovarian cancer? A comparison of survivals and resources in two different periods. International Journal of Gynecological Cancer. 5(2). 148–155. 6 indexed citations
9.
Bertelsen, K. & Jørn Andersen. (1994). Long-term survival and prognostic factors in advanced epithelial ovarian cancer with special emphasis upon the effects of protocol inclusion. International Journal of Gynecological Cancer. 4(3). 180–187. 8 indexed citations
10.
11.
Bertelsen, K., Anders Jakobsen, I. Strøyer, et al.. (1993). A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA). Gynecologic Oncology. 49(1). 30–36. 114 indexed citations
12.
Bertelsen, K. & Lars Bastholt. (1992). High-dose platinum chemotherapy in advanced ovarian cancer: A phase II study. Gynecologic Oncology. 44(1). 79–82. 10 indexed citations
13.
Bertelsen, K.. (1991). Tumor reduction surgery and long‐term survival in advanced ovarian cancer: A DACOVA study. International Journal of Gynecology & Obstetrics. 35(1). 96–97. 1 indexed citations
14.
Bertelsen, K.. (1990). Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecologic Oncology. 38(2). 203–209. 115 indexed citations
15.
Bentzen, Søren M., Ib Balslev, P. Stubbe Teglbjærg, et al.. (1990). Blood transfusion and prognosis in Dukes' B and C colorectal cancer. PubMed. 26(4). 457–463. 34 indexed citations
16.
Pfeiffer, Per, et al.. (1989). Intraperitoneal chemotherapy: Introduction of a new “single use” delivery system—A preliminary report. Gynecologic Oncology. 35(1). 47–49. 12 indexed citations
17.
Bentzen, Søren M., I. Balslev, M. G. Pedersen, et al.. (1988). A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does post-operative radiotherapy change the prognosis?. British Journal of Cancer. 58(2). 195–201. 44 indexed citations
18.
Bertelsen, K. & C. Gadeberg. (1978). Carcinoma of the Eyelid. PubMed. 17(1). 58–64. 19 indexed citations
19.
Andersen, A. P., K. Bertelsen, O. Elbrønd, C. Gadeberg, & C. Lund. (1977). Malignant Tumours of the Oropharynx. Acta Radiologica Therapy Physics Biology. 16(1). 63–72. 4 indexed citations
20.
Bertelsen, K., et al.. (1965). [DEATH DUE TO PENICILLIN. 16 DANISH CASES WITH AUTOPSIES].. PubMed. 73. 173–7. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harrison Ball Breakdown of academic impact, for papers by Giovanna Scarfone Breakdown of academic impact, for papers by M. Lahousen Breakdown of academic impact, for papers by Bonnie Reichman Breakdown of academic impact, for papers by George J. Olt Breakdown of academic impact, for papers by H Lambert Breakdown of academic impact, for papers by Pamela J. Paley Breakdown of academic impact, for papers by C. Lhommé Breakdown of academic impact, for papers by J.G. Aalders Breakdown of academic impact, for papers by Michael Teneriello
Rankless by CCL
2026